Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter
Open Access
- 29 July 1993
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 329 (5), 297-303
- https://doi.org/10.1056/nejm199307293290501
Abstract
Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are uncertain.Keywords
This publication has 15 references indexed in Scilit:
- Preliminary analysis of the Concorde trialThe Lancet, 1993
- When should asymptomatic patients with HIV infection be treated with zidovudine?BMJ, 1992
- A Controlled Trial of Early versus Late Treatment with Zidovudine in Symptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.BMJ, 1992
- Early HIV infection: to treat or not to treat?BMJ, 1990
- Early Treatment for HIVNew England Journal of Medicine, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Plasma Viremia in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1989
- Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected PersonsNew England Journal of Medicine, 1989
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987